Your browser is no longer supported. Please, upgrade your browser.
Trevi Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.77 Insider Own3.05% Shs Outstand21.61M Perf Week-9.01%
Market Cap19.09M Forward P/E- EPS next Y-1.00 Insider Trans0.00% Shs Float20.23M Perf Month0.21%
Income-34.90M PEG- EPS next Q-0.30 Inst Own55.40% Short Float0.57% Perf Quarter-44.29%
Sales- P/S- EPS this Y20.40% Inst Trans14.37% Short Ratio0.40 Perf Half Y-62.76%
Book/sh0.53 P/B1.36 EPS next Y-0.60% ROA-87.00% Target Price8.00 Perf Year-76.12%
Cash/sh1.10 P/C0.65 EPS next 5Y- ROE-174.50% 52W Range0.66 - 3.64 Perf YTD-8.12%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-80.26% Beta-
Dividend %- Quick Ratio3.10 Sales past 5Y- Gross Margin- 52W Low8.73% ATR0.07
Employees14 Current Ratio3.10 Sales Q/Q- Oper. Margin- RSI (14)41.03 Volatility7.28% 9.54%
OptionableNo Debt/Eq1.27 EPS Q/Q17.50% Profit Margin- Rel Volume0.05 Prev Close0.74
ShortableYes LT Debt/Eq0.89 EarningsNov 10 AMC Payout- Avg Volume288.69K Price0.72
Recom1.50 SMA20-2.45% SMA50-20.38% SMA200-56.34% Volume14,170 Change-2.88%
Jun-03-19Initiated SVB Leerink Outperform $14
Jun-03-19Initiated Stifel Buy $20
Jun-03-19Initiated Needham Buy $18
Jun-03-19Initiated BMO Capital Markets Outperform $15
Jan-05-22 07:00AM  
Dec-16-21 04:05PM  
Dec-01-21 08:22AM  
Nov-18-21 10:21AM  
Nov-15-21 07:30AM  
Nov-10-21 04:05PM  
Nov-09-21 07:30AM  
Nov-03-21 04:05PM  
Oct-13-21 04:05PM  
Oct-12-21 05:01AM  
Oct-11-21 07:01AM  
Oct-07-21 04:05PM  
Sep-30-21 06:57PM  
Aug-12-21 04:05PM  
Aug-09-21 04:05PM  
Aug-05-21 04:05PM  
Jun-09-21 07:30AM  
May-13-21 04:05PM  
May-06-21 04:05PM  
Apr-07-21 07:30AM  
Mar-25-21 04:05PM  
Mar-18-21 04:05PM  
Feb-18-21 04:05PM  
Feb-03-21 07:30AM  
Feb-01-21 07:30AM  
Nov-11-20 04:05PM  
Nov-10-20 07:30AM  
Nov-04-20 04:05PM  
Nov-03-20 02:47PM  
Oct-31-20 08:00AM  
Oct-21-20 08:00AM  
Oct-13-20 04:05PM  
Sep-09-20 04:05PM  
Aug-13-20 04:05PM  
Aug-10-20 03:30PM  
Aug-06-20 04:05PM  
Aug-05-20 07:30AM  
Jul-13-20 07:30AM  
Jun-30-20 04:45PM  
Jun-17-20 04:05PM  
Jun-01-20 11:44AM  
May-29-20 04:05PM  
May-07-20 04:05PM  
Apr-08-20 04:05PM  
Mar-16-20 08:00AM  
Feb-20-20 04:05PM  
Feb-18-20 04:05PM  
Feb-07-20 02:27PM  
Dec-11-19 06:45AM  
Nov-14-19 04:05PM  
Nov-13-19 05:01PM  
Nov-08-19 12:08PM  
Sep-05-19 04:05PM  
Aug-12-19 04:05PM  
Aug-09-19 11:40AM  
Jun-13-19 04:09PM  
Jun-03-19 02:35PM  
May-07-19 01:22PM  
May-01-19 10:31AM  
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation; and Rutgers to develop and commercialize products incorporating nalbuphine for any human or animal use. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.